Skip navigation
Speakers

Applying the Latest Technical and Process Innovations to Achieve Commercially Viable Products and Efficacious Patient Outcomes

March 26-27, 2018
  • Washington, DC

Eytan Abraham, PhD
Head of Research & Technology for Emerging Technologies
Lonza

Julie Allickson, PhD
Director, Regenerative Medicine Clinical Center,
Wake Forest Institute for Regenerative Medicine
Wake Forest University School of Medicine

Dolores Baksh, PhD
Innovation Leader, Cell Therapy Technologies
GE Healthcare Life Sciences

Marc-Olivier M. Baradez, PhD
Lead Scientist, Analytical Development
Cell and Gene Therapy Catapult, United Kingdom

Andrew Beavis, PhD
Director, Analytical R&D, Cell Process Development
Celgene

Scott R. Burger, MD
Principal
Advanced Cell & Gene Therapy, LLC

Jason Carstens, PhD
Principal Consultant, Cell Therapy and
Biologics Manufacturing & Development
Cyathlon Bioscience, LLC

Anthony Davies, PhD
Founder & Executive Chairman
Dark Horse Consulting Inc.

Brian Hampson
Vice President, Global Manufacturing Sciences and Technology
Hitachi Chemical Advanced Therapeutics Solutions

Courtney LeBlon, PhD
Senior Biomedical Engineer, Manufacturing Sciences and Technology
Hitachi Chemical Advanced Therapeutics Solutions

Damian Marshall
Head of Analytical Development
Cell Therapy Catapult

Aby Mathew, PhD
Senior Vice President & Chief Technology Officer
BioLife Solutions, Inc.

Ali Mohamed, PhD
VP, CMC
Immatics

Robert A. Preti, PhD
General Manager, Hitachi Chemical Regenerative
Medicine Business Sector, President and CEO
Hitachi Chemical Advanced Therapeutics Solutions, LLC

Senthil Ramaswamy, PhD
Director of Cell Therapy Operations
Lonza Walkersville

Rodney Rietze, PhD
Enabling Technology and Strategic Development,
Cell and Gene Technologies
Novartis

Jon Rowley, PhD
Founder and CTO
RoosterBio Inc.

Sumona Sarkar, PhD
Biomedical Engineer, Biosystems and Biomaterials Division
National Institute of Standard and Technology

Alan K. Smith, PhD
Executive Vice President, Technical Operations
Bellicum Pharmaceuticals

Andrew T. Steinsapir
Consultant
Dark Horse Consulting Inc.

David Stroncek, PhD
Medical Director
NIH

Nick Timmins
VP, Process Sciences
BlueRock Therapeutics

Phil Vanek, PhD
General Manager, Cell Therapy Growth Strategy
GE Healthcare

Wen Bo Wang
Senior Vice President, Cell Therapy Research and
Development, Therapeutics Division
Cellular Dynamics International, a Fujifilm company

Keith Wonnacott, PhD
Executive Director, Regulatory Affairs
Pfizer Inc (invited)

Eytan Abraham, PhD
Head of Research & Technology for Emerging Technologies
Lonza

Julie Allickson, PhD
Director, Regenerative Medicine Clinical Center,
Wake Forest Institute for Regenerative Medicine
Wake Forest University School of Medicine

Dolores Baksh, PhD
Innovation Leader, Cell Therapy Technologies
GE Healthcare Life Sciences

Marc-Olivier M. Baradez, PhD
Lead Scientist, Analytical Development
Cell and Gene Therapy Catapult, United Kingdom

Andrew Beavis, PhD
Director, Analytical R&D, Cell Process Development
Celgene

Scott R. Burger, MD
Principal
Advanced Cell & Gene Therapy, LLC

Jason Carstens, PhD
Principal Consultant, Cell Therapy and
Biologics Manufacturing & Development
Cyathlon Bioscience, LLC

Anthony Davies, PhD
Founder & Executive Chairman
Dark Horse Consulting Inc.

Brian Hampson
Vice President, Global Manufacturing Sciences and Technology
Hitachi Chemical Advanced Therapeutics Solutions

Courtney LeBlon, PhD
Senior Biomedical Engineer, Manufacturing Sciences and Technology
Hitachi Chemical Advanced Therapeutics Solutions

Damian Marshall
Head of Analytical Development
Cell Therapy Catapult

Aby Mathew, PhD
Senior Vice President & Chief Technology Officer
BioLife Solutions, Inc.

Ali Mohamed, PhD
VP, CMC
Immatics

Robert A. Preti, PhD
General Manager, Hitachi Chemical Regenerative
Medicine Business Sector, President and CEO
Hitachi Chemical Advanced Therapeutics Solutions, LLC

Senthil Ramaswamy, PhD
Director of Cell Therapy Operations
Lonza Walkersville

Rodney Rietze, PhD
Enabling Technology and Strategic Development,
Cell and Gene Technologies
Novartis

Jon Rowley, PhD
Founder and CTO
RoosterBio Inc.

Sumona Sarkar, PhD
Biomedical Engineer, Biosystems and Biomaterials Division
National Institute of Standard and Technology

Alan K. Smith, PhD
Executive Vice President, Technical Operations
Bellicum Pharmaceuticals

Andrew T. Steinsapir
Consultant
Dark Horse Consulting Inc.

David Stroncek, PhD
Medical Director
NIH

Nick Timmins
VP, Process Sciences
BlueRock Therapeutics

Phil Vanek, PhD
General Manager, Cell Therapy Growth Strategy
GE Healthcare

Wen Bo Wang
Senior Vice President, Cell Therapy Research and
Development, Therapeutics Division
Cellular Dynamics International, a Fujifilm company

Keith Wonnacott, PhD
Executive Director, Regulatory Affairs
Pfizer Inc (invited)